OHIO LEGISLATIVE SERVICE COMMISSION

Bill Rowland, Director
Julie Rishle, Assistant Director

www.lsc.ohio.gov

Office of Research and Drafting

Legislative Budget Office

R-136-3657

To: The Honorable Stephen A. Huffman
Ohio Senate

From: Emma Carroll, Research Analyst *EC*

Date: June 9, 2026

Subject: Comparison of H.B. 324 As Passed by the House and l_136_1373-5

This table summarizes how l_136_1373-5 differs from the As Passed by the House version of H.B. 324. It addresses only the topics on which the two versions differ substantively. It does not list topics on which the two bills are substantively the same.

Topic	H.B. 324 (As Passed by the House)	l_136_1373-5
Drug types	Addresses prescription drugs that the Director of Heath determines cause severe adverse effects in more than 5% of the drugs' users (R.C. 3715.39).	Instead, addresses prescription drugs for which the United States Food and Drug Administration (FDA) requires risk evaluation and mitigation strategies (REMS) (R.C. 3715.39). (A REMS is a drug safety program that encourages safe behaviors when taking specific medications.[1])

[1] FDA, "Risk Evaluation and Mitigation Strategies | REMS."

Topic	H.B. 324 (As Passed by the House)	I_136_1373-5
Severe adverse effects	Defines severe adverse effects to mean: ▪ Death; ▪ Infection requiring hospitalization; ▪ Hemorrhaging requiring hospitalization; ▪ Organ failure; ▪ Sepsis (R.C. 3715.39(A)(2)).	No provision.
Director of Health determination	Requires the Director of Health to determine if a prescription drug causes severe adverse effects in more than 5% of users (R.C. 3715.39(C)(1)).	No provision.
	Requires the Director to consult with the Superintendent of Insurance and the Executive Directors of the State Board of Pharmacy and State Medical Board when making this determination (R.C. 3715.39(C)(1)(a)).	No provision.
	Requires the Director's determination to be based on insurance claims, patient reports of severe adverse effects to health care professionals, and any applicable data available from the FDA (R.C. 3715.39(C)(1)(b)).	No provision.
	Requires the Director to publish on the Department of Health's website a list of	No provision.

Topic	H.B. 324 (As Passed by the House)	l_136_1373-5
	prescription drugs the Director determines cause adverse effects in more than 5% of users (R.C. 3715.39(C)(2)).	
Prescribing requirements	Establishes conditions when prescribing a drug causing severe adverse effects in more than 5% of the drug's users, including that the prescriber (1) first conduct an in-person examination of the patient, (2) inform the patient of the drug's severe adverse effects, and (3) schedule the patient for a follow-up appointment (R.C. 3715.39(B)).	Similarly, establishes conditions when prescribing a REMS drug, including requiring an in-person examination to be conducted and a follow-up appointment to be scheduled, except that instead of informing the patient of severe adverse effects, the prescriber must inform the patient that the drug is subject to a REMS (R.C. 3715.39(B)).

R-136-3657/th